ELVN Live signals | Maximize Profits with Getagraph.com

SELL 106335 min ago

@ $17.30

Issued: 14 Feb 2024 @ 15:50

Return: -0.69%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 8.67 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer...

Stats
Today's Volume	147 785
Average Volume	262 869
Market Cap	804.12M
EPS	$4.92 ( 2024-03-15 )
Next earnings date	( $-0.580 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.55
ATR14	$0.0880 (0.51%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Patel Anish	Sell	14 903	Employee Stock Option (right to buy)
2024-04-11	Patel Anish	Buy	14 903	Common Stock
2024-04-11	Patel Anish	Sell	17 500	Common Stock
2024-04-11	Lyssikatos Joseph P	Sell	30 000	Stock Option (right to buy)
2024-04-11	Lyssikatos Joseph P	Buy	30 000	Common Stock

INSIDER POWER
-6.16
Last 99 transactions
Buy: 1 710 487 \| Sell: 1 927 419

Volume Correlation

Long: -0.03 (neutral)

Short: 0.70 (moderate)

Signal:(49.732) Neutral

Enliven Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Enliven Therapeutics, Correlation - Currency/Commodity

0.32
( neutral )

0.30
( neutral )

0.00
( neutral )

-0.04
( neutral )

-0.20
( neutral )

-0.12
( neutral )

Enliven Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-297 000 (0.00 %)
EPS:	$-2.01

FY	2023
Revenue:	$0
Gross Profit:	$-297 000 (0.00 %)
EPS:	$-2.01

FY	2022
Revenue:	$0
Gross Profit:	$-622 000 (0.00 %)
EPS:	$-12.08

Financial Reports:

No articles found.

Enliven Therapeutics,

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.